This mechanism provides a potential explanation for the lack of clinical efficacy of GLS inhibitors in ccRCC and suggests a therapeutic avenue to combine HIF2α inhibition with strategies that restore GLS1 clustering. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.